1. A method for modulating the function and / or expression of a polynucleotide of nuclear respiratory factor 1 (NRF1) in a patient’s cells or tissues in vivo or in vitro, comprising: compacting said cells or tissues with at least one antisense oligonucleotide of at least 5 up to 30 nucleotides, wherein said at least one oligonucleotide has a sequence of at least 50% identical to the sequence inverse to the polynucleotide containing from 5 to 30 consecutive nucleotides in the range from 1 up to 810 nucleotides of the sequence SEQ ID NO: 2, thereby modulating the function and / or expression of said polynucleotide of nuclear respiratory factor 1 (NRF1) in cells or tissues of a patient in vivo or in vitro. 2. A method for modulating the function and / or expression of a nuclear respiratory factor 1 polynucleotide (NRF1) in a patient’s cells or tissues in vivo or in vitro, comprising: contacting said cells or tissues with at least one antisense oligonucleotide of 5-30 nucleotides in length wherein said at least one oligonucleotide has a sequence that is at least 50% identical to the sequence inversely complementary to the natural antisense sequence to the nuclear respiratory polynucleotide factor 1 (NRF1), thereby modulating the function and / or expression of said polynucleotide of nuclear respiratory factor 1 (NRF1) in cells or tissues of a patient in vivo or in vitro. 3. A method for modulating the function and / or expression of a nuclear respiratory factor 1 polynucleotide (NRF1) in a patient’s cells or tissues in vivo or in vitro, including1. Способ модулирования функции и/или экспрессии полинуклеотида ядерного респираторного фактора 1 (NRF1) в клетках или тканях пациента in vivo или in vitro, включающий:приведение указанных клеток или тканей в компакт по меньшей мере с одним антисмысловым олигонуклеотидом, составляющим в длину от 5 до 30 нуклеотидов, причем указанный по меньшей мере один олигонуклеотид имеет последовательность, по меньшей мере на 50% идентичную
